The finding that chemogenetic activation of PPGNTS neurons augments semaglutide‐induced eating suppression (Brierley et al., 2021) suggests that potentiating endogenous central GLP‐1 signalling in combination with GLP‐1R agonist drugs could be a valuable pharmacological strategy for obesity (discussed by Trapp and Brierley in this issue). The gene discussed is GCG; the disease is Obesity.